
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.070
Open
1.060
VWAP
1.05
Vol
172.12K
Mkt Cap
28.87M
Low
1.0346
Amount
180.09K
EV/EBITDA(TTM)
--
Total Shares
22.22M
EV
31.09M
EV/OCF(TTM)
--
P/S(TTM)
14.55
Femasys Inc. is a biomedical company. The Company is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
2.50M
+329.86%
--
--
1.70M
+206.36%
--
--
800.00K
+261.21%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by -16.1% over the past three months. During the same period, the stock price has changed by -32.91%.
Revenue Estimates for FY2025
Revise Downward

-16.1%
In Past 3 Month
Stock Price
Go Down

-32.91%
In Past 3 Month
2 Analyst Rating

749.06% Upside
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

749.06% Upside
Current: 1.060

Low
3.00
Averages
9.00
High
15.00

749.06% Upside
Current: 1.060

Low
3.00
Averages
9.00
High
15.00
Jones Trading
Catherine Novack
Strong Buy
Maintains
$10 → $6
2025-05-13
New
Reason
Jones Trading
Catherine Novack
Price Target
$10 → $6
2025-05-13
New
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$15 → $12
2025-05-09
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15 → $12
2025-05-09
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$12 → $15
2025-03-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12 → $15
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-13
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Femasys Inc (FEMY.O) is -1.81, compared to its 5-year average forward P/E of -2.25. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.25
Current PE
-1.81
Overvalued PE
-0.53
Undervalued PE
-3.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
15.98
Current PS
3.65
Overvalued PS
35.36
Undervalued PS
-3.40
Financials
Annual
Quarterly
FY2025Q1
YoY :
+25.86%
341.26K
Total Revenue
FY2025Q1
YoY :
+57.70%
-5.46M
Operating Profit
FY2025Q1
YoY :
+64.06%
-5.91M
Net Income after Tax
FY2025Q1
YoY :
+35.29%
-0.23
EPS - Diluted
FY2025Q1
YoY :
+4.37%
-4.86M
Free Cash Flow
FY2025Q1
YoY :
-0.75%
40.77
Gross Profit Margin - %
FY2025Q1
YoY :
-5.75%
-1.21K
FCF Margin - %
FY2025Q1
YoY :
+30.16%
-1.73K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FEMY News & Events
Events Timeline
2025-03-27 (ET)
2025-03-27
09:03:21
Femasys reports FY24 EPS (85c), consensus (81c)

2025-03-19 (ET)
2025-03-19
09:23:53
Femasys enters partnership with CNY Fertility

2025-03-18 (ET)
2025-03-18
09:05:49
Femasys secures partnerships for commercialization of FemBloc in Spain

Sign Up For More Events
Sign Up For More Events
News
4.0
05-13BenzingaJones Trading Maintains Buy on Femasys, Lowers Price Target to $6
4.0
03-28BenzingaHC Wainwright & Co. Reiterates Buy on Femasys, Maintains $15 Price Target
4.0
03-19BenzingaHC Wainwright & Co. Maintains Buy on Femasys, Raises Price Target to $15
Sign Up For More News
People Also Watch

TSLA
Tesla Inc
349.980
USD
+2.09%

MSFT
Microsoft Corp
454.270
USD
+0.25%

AAPL
Apple Inc
211.260
USD
-0.09%

XOM
Exxon Mobil Corp
108.190
USD
-0.36%

AVGO
Broadcom Inc
228.610
USD
-1.73%

AMZN
Amazon.com Inc
205.590
USD
+0.20%

META
Meta Platforms Inc
640.340
USD
-0.55%

WMT
Walmart Inc
98.240
USD
+1.96%

NVDA
NVIDIA Corp
135.400
USD
+0.42%

ORCL
Oracle Corp
160.490
USD
+0.68%
FAQ

What is Femasys Inc (FEMY) stock price today?
The current price of FEMY is 1.06 USD — it has decreased -0.93 % in the last trading day.

What is Femasys Inc (FEMY)'s business?

What is the price predicton of FEMY Stock?

What is Femasys Inc (FEMY)'s revenue for the last quarter?

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Femasys Inc (FEMY)'s fundamentals?

How many employees does Femasys Inc (FEMY). have?
